title: Idiopathic pulmonary fibrosis: treatment update.
abstract: Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.
authors: Department of Respiratory Medicine, Cork University Hospital, Wilton, Cork, Ireland.
authors: Oisin J
authors: OJ
authors: O'Connell
authors: Marcus P
authors: MP
authors: Kennedy
authors: Michael T
authors: MT
authors: Henry
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods* / Q000639:trends; D018450:Disease Progression; D065128:Endothelin Receptor Antagonists; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000503:physiopathology / Q000628:therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016040:Lung Transplantation; D054539:Medication Therapy Management / Q000639:trends*; D017063:Outcome Assessment, Health Care; D010102:Oxygen Inhalation Therapy / Q000379:methods*; D010166:Palliative Care; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D000975:Antioxidants; D065128:Endothelin Receptor Antagonists; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha